Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025. byPallavi MadhirajuOctober 11, 2025